EREMISS
-
REGORAFENIB: Gastrointestinal cancer drug legends
Regorafenib was first approved by the FDA in September 2012. It is an oral multi-kinase inhibitor developed by Bayer that targets angiogenic, stromal and oncogenic receptor tyrosine kinase. New application of it is also under research according to the public information [ClinicalTrials.gov Identifier: NCT03793361(Study ID Numbers EREMISS)
